Vimarsana
Biggest News Aggregation in the World

Immunogenicity Trial News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Immunogenicity Trial. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Immunogenicity Trial Today - Breaking & Trending Today

Bharat Biotech's COVID-19 vaccine COVAXIN is well tolerated with no serious adverse events as per phase 1 trial results - Vimarsana News

Bharat Biotech's COVID-19 vaccine COVAXIN is well tolerated with no serious adverse events as per phase 1 trial results

» Bharat Biotech's COVID-19 vaccine COVAXIN is well tolerated with no serious adverse events as per phase 1 trial results Bharat Biotech's COVID-19 vaccine COVAXIN is well tolerated with no serious adverse events as per phase 1 trial results PTIDec 17, 2020, 09:18 IST CovaxinBharat Biotech Covaxin, indigenously developed by Bharat Biotech in collaboration with the ICMR, showed that it was was well tolerated in all dose groups with no serious or adverse events. The vaccine induced robust binding and neutralising antibody responses which were comparable to those observed in the convalescent s...

Related Topics:
Immunogenicity Trial
Morning Digest — December 17, 2020 - Vimarsana News

Morning Digest — December 17, 2020

Updated: A select list of stories to read before you start your day Share Article AAA The U.S. Treasury Department has branded Vietnam and Switzerland as currency manipulators while putting China and nine other countries on a watch list in an annual report. (Representational image)   A select list of stories to read before you start your day Phase-1 results show that Covaxin, a proposed COVID-19 vaccine, is safe. The results find it to be well-tolerated in all dose groups, and that it generates immune response according to results released in a preprint paper titled ‘A Phase 1: Safety and...

Bharat Biotech's phase 1 trial findings show COVID-19 vaccine well tolerated; no serious adverse events - Vimarsana News

Bharat Biotech's phase 1 trial findings show COVID-19 vaccine well tolerated; no serious adverse events

Story highlights The document mentions that BBV152 is stored between 2 degrees Celsius and 8 degrees Celsius, which is compatible with all national immunisation programme cold chain requirements and further efficacy trials are underway. The interim findings of phase 1 clinical trial of COVID-19 vaccine Covaxin, indigenously developed by Bharat Biotech in collaboration with the ICMR, showed that it was was well tolerated in all dose groups with no serious or adverse events. The vaccine induced robust binding and neutralising antibody responses which were comparable to those observed in the con...

Bharat Biotech's Covaxin well tolerated with no serious adverse events: Phase 1 trial findings - Vimarsana News

Bharat Biotech's Covaxin well tolerated with no serious adverse events: Phase 1 trial findings

Bharat Biotech's Covaxin well tolerated with no serious adverse events: Phase 1 trial findings Bharat Biotech's Covaxin well tolerated with no serious adverse events: Phase 1 trial findings Bharat Biotech's coronavirus vaccine candidate Covaxin has shown that it was well tolerated in all dose groups with no serious or adverse events in the interim findings of Phase 1 trials. advertisement Covaxin is being indigenously developed by Bharat Biotech in collaboration with the ICMR. Bharat Biotech's coronavirus vaccine candidate Covaxin has shown that it was well tolerated in all dose groups w...

COVID-19 vaccine: Bharat Biotech's Covaxin Phase 1 trial shows it has no serious adverse events - Vimarsana News

COVID-19 vaccine: Bharat Biotech's Covaxin Phase 1 trial shows it has no serious adverse events

COVID-19 vaccine: Bharat Biotech's Covaxin Phase 1 trial shows it has no serious adverse events Pain at the injection site was the most common local adverse event and was well tolerated in all dose groups. Medics prepare to administer COVAXIN, an Indian government-backed experimental COVID-19 vaccine, to a health worker during its trials, in Ahmedabad. (Photo: Reuters) Share Updated: Dec 16, 2020, 09:24 PM IST COVID-19 vaccine Covaxin, indigenously developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR), was well tolerated ...